Ivabradin Medical Valley

Ivabradine, the active ingredient in Ivabradin Medical Valley, is a If channel inhibitor presented as an oral formulation for oral use. It treats chronic stable angina and heart failure with reduced ejection fraction in adult patients. \nGNH India supplies Ivabradin Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradin Medical Valley acts on the cardiac conduction system to lower heart rate, benefiting several cardiovascular conditions.\n\nChronic stable angina: reduces the frequency of angina attacks by decreasing myocardial oxygen demand.\nHeart failure with reduced ejection fraction: improves symptoms and lowers the risk of hospitalization.\nStable coronary artery disease: lowers heart rate to enhance exercise tolerance.

Ivabradin Medical Valley may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.\n\nCommon Side Effects:\n- Phosphenes (luminous visual phenomena)\n- Bradycardia\n- Headache\n- Dizziness\n\nSerious or Rare Side Effects:\n- Severe bradyarrhythmia\n- Atrioventricular block\n- Worsening heart failure\n- Marked hypotension

Before prescribing Ivabradin Medical Valley, clinicians should consider several safety measures.\n- Assess baseline heart rate: ensure resting HR ≥ 60 bpm before initiation.\n- Avoid strong CYP3A4 inhibitors: may raise plasma concentrations.\n- Monitor for symptomatic bradycardia: adjust dose if needed.\n- Use with caution in severe hepatic impairment.\n- Discontinue before elective cardiac surgery to avoid peri‑operative bradycardia.\n- Store at ambient temperature: keep in original container, protect from moisture and light.

Ivabradin Medical Valley can interact with other medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): risk of excessive bradycardia.\n- Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin): may cause severe bradycardia.\n- Other If channel inhibitors: additive effect on heart rate.\n\nModerate Interactions (Monitor Closely):\\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may increase drug levels, monitor HR.\n- QT‑prolonging drugs: monitor ECG for arrhythmia risk.\n- Certain antidepressants affecting CYP3A4 (e.g., sertraline): observe for heart‑rate changes.